Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sihuan to Develop CNS Drugs with Dutch Pharma to-BBB

publication date: Dec 12, 2013
Sihuan Pharma signed a cooperation agreement with Dutch pharmaceutical company to-BBB to develop innovative CNS drugs. Sihuan will gain access to to-BBB’s G-Technology®, a patented delivery system that allows drugs to cross the blood-brain barrier and, at the same time, facilitates sustained release of the active ingredients. Initially, the two companies will perform feasibility studies on certain of Sihuan’s existing drugs. If successful, the tests will lead to a collaborative effort to develop one or more compounds. More details....

Stock Symbol: (HK: 00460)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital